Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMSW) Capital Expenditures (2023 - 2025)

Historic Capital Expenditures for NewAmsterdam Pharma (NAMSW) over the last 3 years, with Q3 2025 value amounting to $42000.0.

  • NewAmsterdam Pharma's Capital Expenditures fell 4400.0% to $42000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $149000.0, marking a year-over-year decrease of 7782.74%. This contributed to the annual value of $672000.0 for FY2024, which is 270000.0% up from last year.
  • According to the latest figures from Q3 2025, NewAmsterdam Pharma's Capital Expenditures is $42000.0, which was down 4400.0% from $88000.0 recorded in Q2 2025.
  • NewAmsterdam Pharma's Capital Expenditures' 5-year high stood at $385000.0 during Q1 2024, with a 5-year trough of $3000.0 in Q4 2023.
  • For the 3-year period, NewAmsterdam Pharma's Capital Expenditures averaged around $76545.5, with its median value being $16000.0 (2025).
  • As far as peak fluctuations go, NewAmsterdam Pharma's Capital Expenditures surged by 540000.0% in 2024, and later tumbled by 9584.42% in 2025.
  • Over the past 3 years, NewAmsterdam Pharma's Capital Expenditures (Quarter) stood at $3000.0 in 2023, then changed by 0.0% to $3000.0 in 2024, then skyrocketed by 1300.0% to $42000.0 in 2025.
  • Its Capital Expenditures stands at $42000.0 for Q3 2025, versus $88000.0 for Q2 2025 and $16000.0 for Q1 2025.